The cr confirmed that the implant procedure was performed in a sterile environment, sterile field handling protocols were used, the procedure was completed in accordance with the product instructions for use, and the sterile barriers of all product used were intact prior to implant.The procedure was completed without complication, and the cr maintained contact with the patient following implant.On (b)(6) 2019, the complaint specialist documented the following: on (b)(6), the patient reported a skin irritation around the implant site to the territory manager.The patient visited the implanting clinician the same day for evaluation.The implanting clinician noticed the patient had a skin rash at the implant site and believed it was due to an irritation caused by the glue and bandages.The implanting clinician does not believe it is attributed to the device.The irritation was treated by the implanting clinician and the device remains implanted.The device is providing therapy to the patient and no other complications were reported.No further information was available for this issue.On august 5, 2020, complaint specialist, reviewed sterilization and packaging records for the respective product lots, stimwave has confirmed that the product was delivered sterile, no trend of skin irritation is evident for swo190925, validated sterilization parameters were used, and sterile barriers were verified to be intact following packaging.The stimulators were reported to meet product specifications.Device can not currently be received by manufacturer for analysis.The device was used for treatment of pain.
|